Aprea Therapeutics (APRE) Other Accumulated Expenses (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Other Accumulated Expenses of $174947.0 for Q1 2026, down 6.22% year-over-year from $186544.0 in Q1 2025, and up 8.41% quarter-over-quarter from $161372.0 in Q4 2025.
Aprea Therapeutics (APRE) Other Accumulated Expenses (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Other Accumulated Expenses for 9 consecutive years, with $174947.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 6.22% year-over-year to $174947.0; the TTM figure through Mar 2026 stood at $174947.0 (down 6.22% YoY), while the FY2025 annual figure was $161372.0, up 3.46% from the prior year.
- Other Accumulated Expenses grew to $174947.0 in Q1 2026 per APRE's latest filing, from $161372.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $382814.0 in Q1 2022 and bottomed at $46603.0 in Q2 2024.
- Historically, Other Accumulated Expenses has averaged $184826.9 across 5 years, with a median of $174126.0 in 2023.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses slumped 65.13% — and 2025, when it surged 197.04%.
- Aprea Therapeutics' Other Accumulated Expenses stood at $196485.0 in 2022, then declined by 11.38% to $174126.0 in 2023, then slipped by 10.42% to $155980.0 in 2024, then climbed by 3.46% to $161372.0 in 2025, then increased by 8.41% to $174947.0 in 2026.
- Business Quant data shows APRE's Other Accumulated Expenses at $174947.0 in Q1 2026, $161372.0 in Q4 2025, and $149976.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 135,743.00 |
| Mar 31, 2026 | 174,947.00 |
| Dec 31, 2025 | 161,372.00 |
| Sep 30, 2025 | 149,976.00 |
| Jun 30, 2025 | 138,428.00 |
| Mar 31, 2025 | 186,544.00 |
| Dec 31, 2024 | 155,980.00 |
| Sep 30, 2024 | 58,288.00 |
| Jun 30, 2024 | 46,603.00 |
| Mar 31, 2024 | 208,784.00 |
| Dec 31, 2023 | 174,126.00 |
| Sep 30, 2023 | 152,770.00 |
| Jun 30, 2023 | 133,657.00 |
| Mar 31, 2023 | 185,491.00 |
| Dec 31, 2022 | 196,485.00 |
| Sep 30, 2022 | 372,340.00 |
| Jun 30, 2022 | 263,452.00 |
| Mar 31, 2022 | 382,814.00 |
| Dec 31, 2021 | 183,189.00 |
| Sep 30, 2021 | 559,068.00 |